Positive response to cancer trial drug

PATIENTS with hereditary cancers including breast, ovarian and prostate, have responded well in preliminary trials to a new drug after other treatments had failed.

The drug, Olaparib, either shrank or stabilised tumours in more than half of the trial group, all of whom had advanced cancers.

One patient given the treatment is still in remission after two years.